Plus Therapeutics Appoints Ron Andrews With $600M Capitalization Track Record
Plus Therapeutics has appointed diagnostics veteran Ron Andrews to its board, leveraging his 35 years of industry leadership, including over $600 million in capitalization and $15 billion in exits. Andrews will drive U.S. and global commercialization of the CNSide CSF Assay Platform for leptomeningeal metastases.
1. Board Appointment and Expertise
Plus Therapeutics has appointed Ron Andrews to its board of directors, bringing over 35 years of experience in diagnostics and molecular diagnostics. He will contribute strategic oversight as the company scales its CNSide CSF Assay Platform in the U.S. and internationally.
2. Industry Leadership and Track Record
Andrews has led divisions at Abbott Diagnostics, Roche Molecular Diagnostics and Thermo Fisher, served as public CEO of Clarient and Oncocyte, and guided venture-backed companies through product development and fundraising. His career includes securing more than $600 million in capitalization and overseeing exits totaling over $15 billion.
3. Strategic Impact on CNSide Commercialization
The appointment positions Plus to leverage Andrews’ global industry connections to accelerate CNSide’s market introduction for leptomeningeal metastases detection. His expertise is expected to optimize commercialization strategy, enhance partnerships and drive value creation for stockholders.